Figure 4
From: Anti-AMPA GluA3 antibodies in Frontotemporal dementia: a new molecular target
Neurobiological effect of GluA3 antibodies in primary rat neurons. (A) Fluorescence immunocytochemistry of GluA3 (green), PSD-95 (red) and MAP2 (blue) in DIV14 neurons treated with CSF with (CSF+) or without (CSF−) anti-GluA3 antibodies at two different dilutions (1:20 and 1:100) for 24 hours. Scale bar, 5 μm. (B) Bar graph representing the percentage of co-localization of GluA3 with PSD-95. Data are presented as mean ± s.e.m, n = 14, one-way ANOVA followed by Tukey as post hoc test; *p < 0.05, **p < 0.01, ***p < 0.001. (C) Bar graph representing the density of GluA3 positive cluster along dendrites. Data are presented as mean ± s.e.m., n = 14, one-way ANOVA followed by Tukey as post hoc test. (D) Confocal images of rat primary hippocampal neurons transfected at DIV8 with GFP and immunolabeled at DIV14 for GFP (green). Scale bar: 5 μm. (E), Bar graph showing the quantification of dendritic spine density. Data are presented as mean ± s.e.m., n = 6–8, one-way ANOVA followed by Tukey as post hoc test; *p < 0.05, **p < 0.01, ***p < 0.001.
